The effects of conjugated linoleic acid supplementation on glycemic control, adipokines, cytokines, malondialdehyde and liver function enzymes in patients at risk of cardiovascular disease: a GRADE-assessed systematic review and dose-response meta-analysis.
Adipokine
Conjugated linoleic acid
Cytokine
Glycemic profile
Meta-analysis
Journal
Nutrition journal
ISSN: 1475-2891
Titre abrégé: Nutr J
Pays: England
ID NLM: 101152213
Informations de publication
Date de publication:
05 Oct 2023
05 Oct 2023
Historique:
received:
17
03
2023
accepted:
20
09
2023
medline:
1
11
2023
pubmed:
5
10
2023
entrez:
4
10
2023
Statut:
epublish
Résumé
The present systematic review and meta-analysis sought to evaluate the effects of conjugated linoleic acid (CLA) supplementation on glycemic control, adipokines, cytokines, malondialdehyde (MDA) and liver function enzymes in patients at risk of cardiovascular disease. Relevant studies were obtained by searching the PubMed, SCOPUS and Web of Science databases (from inception to January 2023). Weighted mean differences (WMD) and 95% confidence intervals (CIs) were pooled using a random-effects model. Heterogeneity, sensitivity analysis, and publication bias were reported using standard methods. A pooled analysis of 13 randomized controlled trials (RCTs) revealed that CLA supplementation led to a significant increment in fasting blood glucose (FBG) (WMD: 4.49 mg/dL; 95%CI: 2.39 to 6.59; P < 0.001), and aspartate aminotransferase (AST) (WMD: 2.54 IU/L; 95%CI: 0.06 to 5.01; P = 0.044). Moreover, CLA supplementation decreased leptin (WMD: -1.69 ng/ml; 95% CI: -1.80 to -1.58; P < 0.001), and interleukin 6 (IL-6) (WMD: -0.44 pg/ml; 95%CI: -0.86 to -0.02; P = 0.037). However, there was no effect on hemoglobin A1c (HbA1c), homeostatic model assessment for insulin resistance (HOMA-IR), C-reactive protein (CRP), tumor necrosis factor alpha (TNF-α), and alanine aminotransferase (ALT) adiponectin compared to the control group. Our findings showed the overall favorable effect of CLA supplementation on the adipokines and cytokines including serum IL-6, and leptin, while increasing FBG and AST. It should be noted that the mentioned metabolic effects of CLA consumption were small and may not reach clinical importance. CRD42023426374.
Sections du résumé
BACKGROUND
BACKGROUND
The present systematic review and meta-analysis sought to evaluate the effects of conjugated linoleic acid (CLA) supplementation on glycemic control, adipokines, cytokines, malondialdehyde (MDA) and liver function enzymes in patients at risk of cardiovascular disease.
METHODS
METHODS
Relevant studies were obtained by searching the PubMed, SCOPUS and Web of Science databases (from inception to January 2023). Weighted mean differences (WMD) and 95% confidence intervals (CIs) were pooled using a random-effects model. Heterogeneity, sensitivity analysis, and publication bias were reported using standard methods.
RESULTS
RESULTS
A pooled analysis of 13 randomized controlled trials (RCTs) revealed that CLA supplementation led to a significant increment in fasting blood glucose (FBG) (WMD: 4.49 mg/dL; 95%CI: 2.39 to 6.59; P < 0.001), and aspartate aminotransferase (AST) (WMD: 2.54 IU/L; 95%CI: 0.06 to 5.01; P = 0.044). Moreover, CLA supplementation decreased leptin (WMD: -1.69 ng/ml; 95% CI: -1.80 to -1.58; P < 0.001), and interleukin 6 (IL-6) (WMD: -0.44 pg/ml; 95%CI: -0.86 to -0.02; P = 0.037). However, there was no effect on hemoglobin A1c (HbA1c), homeostatic model assessment for insulin resistance (HOMA-IR), C-reactive protein (CRP), tumor necrosis factor alpha (TNF-α), and alanine aminotransferase (ALT) adiponectin compared to the control group.
CONCLUSION
CONCLUSIONS
Our findings showed the overall favorable effect of CLA supplementation on the adipokines and cytokines including serum IL-6, and leptin, while increasing FBG and AST. It should be noted that the mentioned metabolic effects of CLA consumption were small and may not reach clinical importance.
PROSPERO REGISTERATION COD
UNASSIGNED
CRD42023426374.
Identifiants
pubmed: 37794481
doi: 10.1186/s12937-023-00876-3
pii: 10.1186/s12937-023-00876-3
pmc: PMC10552395
doi:
Substances chimiques
Leptin
0
Cytokines
0
Linoleic Acids, Conjugated
0
Interleukin-6
0
Adipokines
0
Malondialdehyde
4Y8F71G49Q
Blood Glucose
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Iran J Med Sci. 2019 Sep;44(5):359-373
pubmed: 31582860
Arch Iran Med. 2019 May 01;22(5):255-261
pubmed: 31256599
Avicenna J Phytomed. 2020 May-Jun;10(3):305-315
pubmed: 32523885
J Lipid Res. 2003 Dec;44(12):2234-41
pubmed: 12923219
J Am Coll Cardiol. 2019 Nov 19;74(20):2529-2532
pubmed: 31727292
J Nutr. 2011 Jul;141(7):1286-91
pubmed: 21593349
Croat Med J. 2016 Aug 31;57(4):331-42
pubmed: 27586548
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
J Cardiol. 2014 Apr;63(4):250-9
pubmed: 24355497
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Am J Clin Nutr. 2004 Sep;80(3):614-20
pubmed: 15321800
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
J Oleo Sci. 2015;64(5):539-51
pubmed: 25843278
Am J Clin Nutr. 2004 Aug;80(2):279-83
pubmed: 15277146
Immunity. 2019 Apr 16;50(4):941-954
pubmed: 30995508
Lipids. 2000 Jul;35(7):783-8
pubmed: 10941880
Biochim Biophys Acta. 2010 Dec;1801(12):1375-85
pubmed: 20800698
Diabetes Care. 2002 Sep;25(9):1516-21
pubmed: 12196420
J Nutr Biochem. 2011 Jul;22(7):656-64
pubmed: 20965713
J Diabetes Metab Disord. 2013 Jul 20;12(1):42
pubmed: 23870044
J Nutr Biochem. 2012 May;23(5):487-93
pubmed: 21684141
Mol Nutr Food Res. 2010 Jan;54(1):17-36
pubmed: 19760681
Endocr Metab Immune Disord Drug Targets. 2017;17(1):5-18
pubmed: 28176632
Arch Latinoam Nutr. 2006 Jun;56(2):123-34
pubmed: 17024956
FASEB J. 2005 Oct;19(12):1746-8
pubmed: 16055499
Pharmacol Res. 2022 Dec;186:106518
pubmed: 36270407
Genes Nutr. 2012 Oct;7(4):499-509
pubmed: 22399314
Cardiovasc Hematol Disord Drug Targets. 2021;21(3):150-161
pubmed: 34852755
Front Immunol. 2023 Feb 22;14:1092077
pubmed: 36911696
Sci Rep. 2018 Feb 28;8(1):3764
pubmed: 29491346
Transl Res. 2017 May;183:57-70
pubmed: 28130064
Am J Physiol. 1999 Apr;276(4):R1172-9
pubmed: 10198400
Prostaglandins Other Lipid Mediat. 2022 Dec;163:106666
pubmed: 35914666
BMC Med Res Methodol. 2005 Apr 20;5:13
pubmed: 15840177
J Nutr. 2010 May;140(5):919-24
pubmed: 20220207
J Nutr. 2003 Jan;133(1):257S-260S
pubmed: 12514304
Cardiovasc Ther. 2017 Dec;35(6):
pubmed: 28556504
Endocr Metab Immune Disord Drug Targets. 2018;18(3):185-193
pubmed: 29219061
Med Sci Sports Exerc. 2004 May;36(5):814-20
pubmed: 15126715
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Ren Fail. 2003 Nov;25(6):953-66
pubmed: 14669854
J Clin Endocrinol Metab. 2017 Jan 1;102(1):132-140
pubmed: 27778642
Nutrition. 2016 Feb;32(2):166-73
pubmed: 26541717
Lipids. 2010 Nov;45(11):1035-45
pubmed: 20853155
Diabetes Care. 2013 Aug;36 Suppl 2:S259-63
pubmed: 23882055
Vasc Health Risk Manag. 2012;8:661-7
pubmed: 23271912
Med J Islam Repub Iran. 2022 Jul 04;36:73
pubmed: 36128278
Metabolism. 2007 Dec;56(12):1601-11
pubmed: 17998009
Atherosclerosis. 2006 Sep;188(1):167-74
pubmed: 16289507
Am J Clin Nutr. 2009 Sep;90(3):468-76
pubmed: 19535429
J Int Soc Sports Nutr. 2015 Sep 17;12:36
pubmed: 26388708
Eur J Endocrinol. 2006 Oct;155(4):615-22
pubmed: 16990662
J Pak Med Assoc. 2000 Aug;50(8):261-4
pubmed: 10992710
Am J Clin Nutr. 2004 Oct;80(4):887-95
pubmed: 15447895
Clin Nutr ESPEN. 2022 Jun;49:121-128
pubmed: 35623803
Nutrients. 2020 Jun 17;12(6):
pubmed: 32560516
Eur J Clin Nutr. 2018 Aug;72(8):1071-1082
pubmed: 29288248
Int J Obes Relat Metab Disord. 2004 Aug;28(8):941-55
pubmed: 15254484
Eur J Pharmacol. 2016 Aug 15;785:87-95
pubmed: 25987426
Am J Clin Nutr. 2004 Dec;80(6):1626-33
pubmed: 15585778
Am J Hypertens. 2009 Jun;22(6):680-6
pubmed: 19300423
ARYA Atheroscler. 2013 Nov;9(6):311-8
pubmed: 24575132
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120